Announced details
Polycythemia vera (PV), erythrocytosis and hematologic diseases
The company will present the results of its clinical study of PPMX-T003 at the ASH Annual Meeting.
A hematology society. The 68th Annual Meeting is scheduled to be held in New Orleans, Louisiana, and online from 12 to 15 December 2026. Other details: Not disclosed
Patent No. 4870348 (ICOS method)
Head office: Chuo-ku, Tokyo
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Published abstract from the 68th ASH Annual Meeting, abstract No. 3802
| Item | Details |
|---|---|
| Names of Products / Services Covered | PPMX-T003 |
| Counterparty | American Society of Hematology (ASH) |
| Counterparty overview | A hematology society. The 68th Annual Meeting is scheduled to be held in New Orleans, Louisiana, and online from 12 to 15 December 2026. Other details: Not disclosed |
| Relationship with the Company | The company will present the results of its clinical study of PPMX-T003 at the ASH Annual Meeting. |
| Launch date | 13 December 2026 (scheduled presentation date and time) |
| Applicable area | Polycythemia vera (PV), erythrocytosis and hematologic diseases |
| Registration number and expiry date | Patent No. 4870348 (ICOS method) |
| Location | Head office: Chuo-ku, Tokyo |
| Source | Published abstract from the 68th ASH Annual Meeting, abstract No. 3802 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the presentation was accepted for the 68th ASH Annual Meeting and the abstract was published.